Researchers
Daniela Salvemini
Summary
Subjects with many cancers are at high risk of developing painful chemotherapy-induced peripheral neuropathy (CIPN) which can prematurely limit therapy and adversely impact quality of life. It is estimated that the incidence of CIPN is 60 to 90 percent in subjects receiving most chemotherapy regimens. The administration of a pharmaceutical composition comprising an A3 adenosine (A3AR) agonist has been found to alleviate the symptoms of neuropathic pain regardless of the cause or location, or severity. Numerous examples are disclosed.
Intellectual Property Status
- U.S. patent pending